Dingchi Biology

About Dingchi Biology

Beijing Dingchi Biology Technology Co., Ltd., operating under the name Vbiosci, is a biopharmaceutical entity established in 2016 with a strategic focus on animal health and bioprocess solutions. The company was founded by Dr. Ma Ningning, a biopharmaceutical engineering expert with a Ph.D. from Ohio State University and approximately two decades of experience, including a senior R&D role at Pfizer. His extensive background in vaccine research and antibody drug development provides the technical foundation for the company's direction. The founding team comprises professionals from prominent international pharmaceutical and animal health corporations, collectively bringing over 20 years of expertise in immunology and animal vaccine development.

The company's operations are twofold, creating a synergistic business model. The primary segment concentrates on developing and commercializing advanced veterinary vaccines and biopharmaceuticals. Its R&D pipeline covers poultry, livestock, and companion animals, targeting both innovative and high-demand products. This division leverages technologies in subunit and genetic engineering to create a new generation of fully suspended veterinary vaccines. The second pillar of its business is its wholly-owned subsidiary, Yishengke (壹生科), which addresses critical supply chain needs within the biopharmaceutical industry. Yishengke, founded in 2013, specializes in the R&D and production of key raw materials, including high-quality serum-free cell culture media and chromatography resins used for protein and antibody purification. This vertical integration not only supports Dingchi's internal development but also serves a broad client base of over 500 entities, including companies in antibody, vaccine, and cell and gene therapy sectors.

Dingchi Biology generates revenue through multiple streams. It commercializes its own line of animal health products, such as the "Dingban" (鼎伴) brand of functional pet foods for cats with human allergies. It also supplies essential raw materials to other biopharma companies through its subsidiary. The company's business strategy involves a comprehensive approach encompassing in-house research, manufacturing, sales, and service. Since its inception, the company has secured significant funding through multiple rounds (A, A+, B, B+, B++), attracting investments from notable firms like Huagai Capital, 3E Bioventures Capital, and China Merchants Capital, which has fueled the expansion of its product pipeline and manufacturing capabilities.